Glycode SAS, a biotechnology company, operates in the field of protein glycosylation in France. It provides and licenses GlycodExpress, a yeast based technological platform for the production of recombinant therapeutic glycoproteins for therapeutic purposes, such as antibodies, EPOs, and growth factors, as well as allows humanization of N-glycosylation in Saccharomyces cerevisiae. The company also offers on-demand production and purification services, from the conception and synthesis of optimized expression vectors for protein expression in glycoengineered yeasts to the early steps of production process. Glycode SAS serves biotechnology and pharmaceutical companies. The company was founded in 2004 and is based in Uzerche, France.
Funding Rounds (1) - $4.31MUpdate
Current Team (1)Update
|Jul 21, 2010||glycode.fr - Glycode raises 4310700 in venture round|
6 Rue Porte Baffat